N@N

ICON Announces Appointment of Cathrin Petty to Board of Directors

_{//health-fitness.news-articles.net/content/2010/ .. ment-of-cathrin-petty-to-board-of-directors.html}
^{Published in Health and Fitness on Tuesday, October 26th 2010 at 1:40 GMT by Market Wire}  

DUBLIN--([ BUSINESS WIRE ])--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Cathrin Petty as a non-executive Director. Cathrin was appointed unanimously by ICONa�s board of directors and, in accordance with the companya�s Articles of Association, will stand for re-election by ICONa�s shareholders at the Companya�s next annual general meeting.

"We are delighted to welcome Cathrin to the ICON Board"

Cathrin is a Special Partner at Vitruvian Partners LLP and also serves as a Non Executive Director for the NHS (Strategic Health Authority for Greater London), a Non Executive Director for Circassia Ltd and an advisor to Merz Pharma GmBH

Between 2000 and 2010 Cathrin was a Healthcare Partner in Apex Partners LLP with responsibility for originating, executing, monitoring and exiting healthcare private equity investments with a specific focus on Life Science investments in the pharmaceutical and medical device arena. Her early career included Senior Associate and Research Analyst roles at Schroder Ventures Life Sciences and Schroders Investment Management.

aWe are delighted to welcome Cathrin to the ICON Board,a commented Chairman, Dr. Bruce Given. aHer financial experience, coupled with her extensive expertise in the analysis of healthcare industry trends, strategies and financial performance will complement the strengths and talents of our existing board members.a

Notes to Editors:

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programmes that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,700 employees, operating from 71 offices in 39 countries.

ICON/ICLR-F